December 16, 2016 / 6:11 PM / 7 months ago

BRIEF-Xbiotech says received Day 180 List Of Outstanding Issues from EMA for Xilonix - SEC filing

1 Min Read

Dec 16 (Reuters) - Xbiotech Inc -

* Xbiotech-Announced it received Day 180 List Of Outstanding Issues from European Medicines Agency's Committee for Medicinal Products for Human Use

* Major objections remain relating to clinical and quality matters for Xilonix

* Xbiotech Inc- Day 180 List Of Outstanding Issues in connection with company's marketing authorization application for Xilonix

* No objections remain regarding non-clinical aspects of co's marketing authorization application for Xilonix

* Xbiotech Inc - Company believes CHMP's requests are addressable

* Xbiotech - Plans to submit responses to List Of Outstanding Issues within 60 days, in line with updated regulatory timetable. Source text: (bit.ly/2hPfUyC) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below